Povidone Iodine 5% 4.0ml

Product Description

Povidone Iodine 5% 4.0ml offers a number of benefits to the ocular surgical team:

• 4.0ml single use container
• Double sterile wrapped to minimise risk of contamination
• Alcohol free formula
• No requirement for two products to be used at the point of surgery – 4.0ml product covers both the ocular region and the ocular surface. Currently, a second Povidone Iodine 5% 0.4ml single use product is required for the ocular surface in addition to a source of Povidone Iodine for the ocular region

There is no further need to import or prepare compounded forms of Povidone Iodine 5% for ocular surgery

How to use Povidone Iodine 5% 4.0ml 

Povidone Iodine 5% 4.0ml can be opened inside the surgical theatre due to the double sterile packaging.

– Adults (including the elderly)

– To be applied topically to the area around the eyes and ocular surfaces prior to surgery.

– Paediatric population

– The adult dose may be used in infants, children and adolescents.

Method of Administration

Wash hands thoroughly before use.

Saturate sterile wadding with the povidone iodine solution contained in the bottle and start preparing lashes and eyelid margins.

Repeat the process for the eyelids, cheeks and forehead in a circular manner until the entire surgical field is cleaned.

Repeat this process three times.

Irrigate the cornea, conjunctiva and palpebral fornixes with the ophthalmic solution. Leave the solution on the area for two minutes.

Remove the povidone iodine from the ocular surface by irrigating the cornea, conjunctiva and palpebral fornixes with sterile sodium chloride 0.9% solution until the characteristic colour of the iodine solution disappears.

Do not touch the eye with the container nozzle.

All enquiries for Povidone Iodine 5% should be directed to Penlan Pharmaceuticals or to your preferred mainline wholesaler.

Should you require any further information, please do not hesitate to contact us.

Date of preparation March 2024

Code Number  UK100033/006 v1.0

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Penlan Pharmaceuticals Ltd. (Tel: 0345 241 4330)